Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer

Carmine Nunziata, Andrea Polo, Angela Sorice, Francesca Capone, Marina Accardo, Eliana Guerriero, Federica Zito Marino, Michele Orditura, Alfredo Budillon, Susan Costantini

Research output: Contribution to journalArticle

Abstract

Selenophosphate synthetase 2 (SEPHS2) synthesizes selenide and ATP into selenophosphate, the selenium donor for selenocysteine (Sec), which is cotranslationally incorporated into selenoproteins. The action and regulatory mechanisms of SEPHS2 as well as its role in carcinogenesis (especially breast cancer) remain ambiguous and need further clarification. Therefore, lacking an experimentally determined structure for SEPHS2, we first analyzed the physicochemical properties of its sequence, modeled its three-dimensional structure and studied its conformational behavior to identify the key residues (named HUB nodes) responsible for protein stability and to clarify the molecular mechanisms by which it induced its function. Bioinformatics analysis evidenced higher amplification frequencies of SEPHS2 in breast cancer than in other cancer types. Therefore, because triple negative breast cancer (TNBC) is biologically the most aggressive breast cancer subtype and its treatment represents a challenge due to the absence of well-defined molecular targets, we evaluated SEPHS2 expression in two TNBC cell lines and patient samples. We demonstrated mRNA and protein overexpression to be correlated with aggressiveness and malignant tumor grade, suggesting that this protein could potentially be considered a prognostic marker and/or therapeutic target for TNBC.

Original languageEnglish
Article number16131
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Triple Negative Breast Neoplasms
Selenocysteine
Breast Neoplasms
Proteins
Selenoproteins
Protein Stability
Selenium
Computational Biology
Neoplasms
Carcinogenesis
Adenosine Triphosphate
selenophosphate synthetase
human selenophosphate synthetase 2
Cell Line
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. / Nunziata, Carmine; Polo, Andrea; Sorice, Angela; Capone, Francesca; Accardo, Marina; Guerriero, Eliana; Marino, Federica Zito; Orditura, Michele; Budillon, Alfredo; Costantini, Susan.

In: Scientific Reports, Vol. 9, No. 1, 16131, 01.12.2019.

Research output: Contribution to journalArticle

Nunziata, C, Polo, A, Sorice, A, Capone, F, Accardo, M, Guerriero, E, Marino, FZ, Orditura, M, Budillon, A & Costantini, S 2019, 'Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer', Scientific Reports, vol. 9, no. 1, 16131. https://doi.org/10.1038/s41598-019-52718-0
Nunziata, Carmine ; Polo, Andrea ; Sorice, Angela ; Capone, Francesca ; Accardo, Marina ; Guerriero, Eliana ; Marino, Federica Zito ; Orditura, Michele ; Budillon, Alfredo ; Costantini, Susan. / Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{c3cec229d0a4492593a5ce85b0510421,
title = "Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer",
abstract = "Selenophosphate synthetase 2 (SEPHS2) synthesizes selenide and ATP into selenophosphate, the selenium donor for selenocysteine (Sec), which is cotranslationally incorporated into selenoproteins. The action and regulatory mechanisms of SEPHS2 as well as its role in carcinogenesis (especially breast cancer) remain ambiguous and need further clarification. Therefore, lacking an experimentally determined structure for SEPHS2, we first analyzed the physicochemical properties of its sequence, modeled its three-dimensional structure and studied its conformational behavior to identify the key residues (named HUB nodes) responsible for protein stability and to clarify the molecular mechanisms by which it induced its function. Bioinformatics analysis evidenced higher amplification frequencies of SEPHS2 in breast cancer than in other cancer types. Therefore, because triple negative breast cancer (TNBC) is biologically the most aggressive breast cancer subtype and its treatment represents a challenge due to the absence of well-defined molecular targets, we evaluated SEPHS2 expression in two TNBC cell lines and patient samples. We demonstrated mRNA and protein overexpression to be correlated with aggressiveness and malignant tumor grade, suggesting that this protein could potentially be considered a prognostic marker and/or therapeutic target for TNBC.",
author = "Carmine Nunziata and Andrea Polo and Angela Sorice and Francesca Capone and Marina Accardo and Eliana Guerriero and Marino, {Federica Zito} and Michele Orditura and Alfredo Budillon and Susan Costantini",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-52718-0",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer

AU - Nunziata, Carmine

AU - Polo, Andrea

AU - Sorice, Angela

AU - Capone, Francesca

AU - Accardo, Marina

AU - Guerriero, Eliana

AU - Marino, Federica Zito

AU - Orditura, Michele

AU - Budillon, Alfredo

AU - Costantini, Susan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Selenophosphate synthetase 2 (SEPHS2) synthesizes selenide and ATP into selenophosphate, the selenium donor for selenocysteine (Sec), which is cotranslationally incorporated into selenoproteins. The action and regulatory mechanisms of SEPHS2 as well as its role in carcinogenesis (especially breast cancer) remain ambiguous and need further clarification. Therefore, lacking an experimentally determined structure for SEPHS2, we first analyzed the physicochemical properties of its sequence, modeled its three-dimensional structure and studied its conformational behavior to identify the key residues (named HUB nodes) responsible for protein stability and to clarify the molecular mechanisms by which it induced its function. Bioinformatics analysis evidenced higher amplification frequencies of SEPHS2 in breast cancer than in other cancer types. Therefore, because triple negative breast cancer (TNBC) is biologically the most aggressive breast cancer subtype and its treatment represents a challenge due to the absence of well-defined molecular targets, we evaluated SEPHS2 expression in two TNBC cell lines and patient samples. We demonstrated mRNA and protein overexpression to be correlated with aggressiveness and malignant tumor grade, suggesting that this protein could potentially be considered a prognostic marker and/or therapeutic target for TNBC.

AB - Selenophosphate synthetase 2 (SEPHS2) synthesizes selenide and ATP into selenophosphate, the selenium donor for selenocysteine (Sec), which is cotranslationally incorporated into selenoproteins. The action and regulatory mechanisms of SEPHS2 as well as its role in carcinogenesis (especially breast cancer) remain ambiguous and need further clarification. Therefore, lacking an experimentally determined structure for SEPHS2, we first analyzed the physicochemical properties of its sequence, modeled its three-dimensional structure and studied its conformational behavior to identify the key residues (named HUB nodes) responsible for protein stability and to clarify the molecular mechanisms by which it induced its function. Bioinformatics analysis evidenced higher amplification frequencies of SEPHS2 in breast cancer than in other cancer types. Therefore, because triple negative breast cancer (TNBC) is biologically the most aggressive breast cancer subtype and its treatment represents a challenge due to the absence of well-defined molecular targets, we evaluated SEPHS2 expression in two TNBC cell lines and patient samples. We demonstrated mRNA and protein overexpression to be correlated with aggressiveness and malignant tumor grade, suggesting that this protein could potentially be considered a prognostic marker and/or therapeutic target for TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85074623923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074623923&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-52718-0

DO - 10.1038/s41598-019-52718-0

M3 - Article

C2 - 31695102

AN - SCOPUS:85074623923

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16131

ER -